SCHEMBL14686475

SCHEMBL14686475

Fc1ccc(-c2cc(C3CCNCC3)n(-c3ncccn3)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PRCP P42785 6/20 0.56
▸ PLAT P00750 3/20 0.53
▸ MKNK1 Q9BUB5 1/20 0.48
▸ MKNK2 Q9HBH9 1/20 0.48
▸ HTR1A P08908 3/20 0.41
▸ SLC6A2 P23975 3/20 0.41
▸ SLC6A4 P31645 3/20 0.41
▸ SLC6A3 Q01959 1/20 0.41
▸ MAPK11 Q15759 2/20 0.40
▸ MAPK14 Q16539 2/20 0.40
▸ MAPK13 O15264 1/20 0.40
▸ RAF1 P04049 1/20 0.40
▸ MAPK9 P45984 1/20 0.40
▸ MAPK12 P53778 1/20 0.40
▸ JAK2 O60674 1/20 0.38
▸ JAK3 P52333 1/20 0.38
▸ PTK2 Q05397 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12185513 0.89 PRCP (0.62) PRCPPLATHTR1ASLC6A2SLC6A4
SCHEMBL12185546 0.87 PLAT (0.50) PRCPPLATMKNK1MKNK2HTR1A
SCHEMBL2599453 0.86 PRCP (0.51) PRCPPLATMKNK1MKNK2MAPK11
SCHEMBL12184145 0.81 PRCP (0.52) PRCPPLAT
SCHEMBL12184727 0.78 PRCP (0.54) PRCPPLAT
SCHEMBL14749308 0.78 PRCP (0.54) PRCPPLAT
SCHEMBL14686540 0.77 PRCP (0.83) PRCP
SCHEMBL14736875 0.76 PRCP (0.59) PRCP
SCHEMBL14737072 0.76 PRCP (0.52) PRCP
SCHEMBL14686671 0.76 PRCP (0.56) PRCPPLATMKNK1MKNK2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2568812-B1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME (US) 2016-10-26 — — EP disclosed
EP-2568812-B1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME (US) 2016-10-26 — — EP disclosed
US-9365539-B2 Prolylcarboxypeptidase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-06-14 — — US disclosed
US-9365539-B2 Prolylcarboxypeptidase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-06-14 — — US disclosed
US-9365539-B2 Prolylcarboxypeptidase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-06-14 — — US disclosed
US-20130040929-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-02-14 — — US disclosed
US-20130040929-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-02-14 — — US disclosed
US-20130040929-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-02-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040929-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS PRCP, PREP, ENPEP PRCP 1/4885PLAT 123/4885MKNK1 1365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback